Search clinical trials for: Antitachycardiac Pacing(ATP)

Total 915 results

Bristlecone Health, Inc.
University of Minnesota

Completed

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

Metabolic Syndrome | Mild Cognitive Impairment

United States
Cheng-Hsin General Hospital

Completed

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Heart Failure | Hypotension

Taiwan
Assistance Publique - Hôpitaux de Paris

Recruiting

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults (GRAAPH2014)

Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

France
AbbVie

Completed

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Anxiety Disorders,Generalized Anxiety Disorder

United States
Boehringer Ingelheim

Terminated

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Schizophrenia

United States, Korea, Republic of, Canada, Japan, Spain, Taiwan, France
Novartis

Completed

Switching to Iloperidone From Other Antipsychotics in Schizophrenia (i-FANS)

Schizophrenia

United States
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Mexico
Athira Pharma

Enrolling by invitation

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States, Australia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8

United States
Suven Life Sciences Limited

Recruiting

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Agitation | Alzheimer's Type Dementia

Croatia, United States, Poland, Serbia
Karuna Therapeutics

Active, not recruiting

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

Schizophrenia

United States
AbbVie

Withdrawn

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone (CAR aGAD Ph 2)

Generalized Anxiety Disorder

United States
Bayer

Completed

Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam

Biological Availability

Germany
Forest Laboratories

Completed

A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-23)

Major Depressive Disorder

United States, Canada
AbbVie

Recruiting

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Schizophrenia | Bipolar I Disorder | Autism Spectrum Disorder (ASD)

United States, Puerto Rico
Assembly Biosciences

Completed

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

Chronic Hepatitis B

United States
Cognito Therapeutics, Inc.

Enrolling by invitation

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia Moderate

United States
Forest Laboratories

Completed

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) (VLZ-MD-22)

Major Depressive Disorder

United States, Canada
Novartis Pharmaceuticals
National Institute on Aging (NIA); Amgen; Banner Alzheimer's Institute

Terminated

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)

Alzheimers Disease

United States, Belgium, United Kingdom, Germany, Australia, Canada, Spain, Finland, Switzerland, Netherlands
Novartis Pharmaceuticals
Amgen; Banner Alzheimer's Institute

Terminated

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2)

Alzheimers Disease

Spain, United States, Belgium, Italy, Germany, Australia, Israel, Taiwan, Japan, Canada, Korea, Republic of, United Kingdom, France, China, Argentina, Finland, Singapore, Portugal, Chile, Mexico, Switzerland, Netherlands, Iceland, Puerto... and more
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Forest Laboratories

Completed

Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

Depression | Bipolar Disorder

United States, Bulgaria, Poland, Puerto Rico, Lithuania, Estonia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

Neurobehavioral Disinhibition

United States
Alzheon Inc.

Enrolling by invitation

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

Early Alzheimer's Disease

United States, Spain, Canada, Netherlands, Czechia, United Kingdom, France, Germany, Iceland
Pfizer

Terminated

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Alzheimer's Disease

United States, Spain, Canada, United Kingdom, Germany, Chile, France
Janssen Research & Development, LLC

Recruiting

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE)

Depressive Disorder, Major

United States, Korea, Republic of, Brazil, Spain, Argentina, United Kingdom, Sweden, Italy, Germany, France, Canada
Cognito Therapeutics, Inc.

Recruiting

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011) (Hope)

Cognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditions

United States
Suven Life Sciences Limited

Completed

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Alzheimer's Disease

United States
Athira Pharma

Active, not recruiting

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD)

Alzheimer Disease | Dementia of Alzheimer Type

United States
Alector Inc.
AbbVie

Active, not recruiting

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2)

Alzheimer Disease

United States, Spain, France, Germany, Australia, Canada, Poland, Italy, Argentina, Netherlands, United Kingdom, New Zealand
AbbVie

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Depression | Bipolar I Disorder

United States, Puerto Rico, Russian Federation
TauRx Therapeutics Ltd

Completed

Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

Alzheimer Disease

United States, Spain, Poland, Belgium, France, United Kingdom, Italy, Canada
Cassava Sciences, Inc.
Premier Research Group plc

Active, not recruiting

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease (RETHINK-ALZ)

Alzheimer Disease

United States, Australia, Canada
Cerecin

Completed

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH-AD)

Alzheimer's Disease

United States
Novartis Pharmaceuticals

Terminated

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Puerto Rico
TauRx Therapeutics Ltd

Completed

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Alzheimer's Disease

United States, Spain, Canada, Belgium, France, Italy, Croatia, Finland, Germany, United Kingdom, Australia, Netherlands
Cassava Sciences, Inc.

Enrolling by invitation

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Alzheimer Disease

United States, Canada, Puerto Rico
Cortexyme Inc.

Completed

GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

Alzheimer Disease

United States, Spain, Poland, United Kingdom, France, Netherlands
Abbott Medical Devices

Completed

Lead Registry for Optim Leads (OPTIMUM)

Optim Lead Insulation Related Adverse Events

United States, Belgium, Germany
LivaNova

Recruiting

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Treatment Resistant Depression

United States
Alzheon Inc.
National Institute on Aging (NIA)

Active, not recruiting

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4)

Early Alzheimer's Disease

United States, Spain, Canada, Netherlands, Czechia, United Kingdom, France, Germany, Iceland
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Sweden, Poland, South Africa, Belgium, Czechia, Estonia, Finland, Hungary, Romania
Novartis

Completed

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 (ACTION)

Alzheimer's Disease

United States, Puerto Rico
Naurex, Inc, an affiliate of Allergan plc

Completed

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Depressive Disorder, Major

United States
AbbVie

Terminated

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

Schizophrenia

United States, Serbia, Korea, Republic of, Malaysia, Poland, Bulgaria, Ukraine, Puerto Rico, Romania, Taiwan, Thailand
ACADIA Pharmaceuticals Inc.

Completed

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Serbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
Boehringer Ingelheim

Active, not recruiting

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

Schizophrenia

United States, Spain, Korea, Republic of, Croatia, Malaysia, Japan, Singapore, Chile, Serbia, Poland, Hungary, Argentina, France, Slovakia, Brazil, Netherlands, Romania, Ukraine
ACADIA Pharmaceuticals Inc.

Completed

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Dementia-related Psychosis

United States, Spain, Poland, Ukraine, Chile, Czechia, United Kingdom, Bulgaria, France, Germany, Italy, Serbia, Slovakia

Search clinical trials for: Antitachycardiac Pacing(ATP)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations